<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20141230020486N5</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-10-14</date_registration>
      <primary_sponsor>Mashhad University of Medical Sciences</primary_sponsor>
      <public_title>Effect of propolis in pain of Endometriosis</public_title>
      <acronym></acronym>
      <scientific_title>The effect of propolis supplementation in reducing pain in patients with Endometriosis</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-10-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/71379</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization is according to the block method with various block sizes. A random chain of two groups includes treatment (T) and control (C) with a ratio of 1:1 in blocks of size 4 and 6 (7 blocks of 4 and 2 blocks of 6) with the help of www.sealedenvelope.com for 40 volunteers. Also, a 4-digit personal ID is created for each volunteer. To hide the random allocation, boxes of the same shape are used for the drug and placebo, and these boxes correspond to the random sequence of T and C with the drug or placebo, the row number 1 to 40 and the ID code are recorded on it. The steps of preparation and arrangement of the random sequence are only at the disposal of the epidemiologist of the study. The number box placed is provided to the admissions officer of the applicants. When every candidate enters the study, the box corresponding to the candidate's number is provided to him, Blinding description: All the study subjects, including the patients, the attending physician, and the project manager, are unaware of the allocation of patients to groups and the medicine they receive, and only the epidemiologist (responsible for randomization and final analysis of the data) is aware of the allocation method. The epidemiologist is neither involved in the prescription nor in the evaluation of the treatment and is only responsible for maintaining the codes and providing the numbered boxes containing the drug or placebo to the attending physician. On the boxes, only rows number 1 to 40 and the ID code are recorded, and the propolis or placebo tablets inside the box are exactly the same shape, size, and color. Therefore, it is not possible to identify the drug from the placebo for the patients, the attending physician, and the project manager. After taking the drug or placebo for 4 months, the patient is evaluated in the hospital clinic by the attending physician who does not know that he has received the drug or placebo and only knows about the ID code. Finally, the attending physician gives the evaluation results to the epidemiologist based on the code.</study_design>
      <phase>3</phase>
      <hc_freetext>Condition 1: Endometriosis of pelvic peritoneum. Condition 2: Endometriosis of rectovaginal septum and vagina.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: standard treatment (progesterone drugs) along with propolis tablets 500 mg twice a day for 4 months. These tablets are made by the pharmaceutical laboratory of the Mashhad Faculty of Pharmacy and look exactly like placebo tablets. Intervention 2: Control group: standard treatment (progesterone drugs) along with placebo tablets twice a day for 4 months. These tablets are made by the pharmaceutical laboratory of the Mashhad Faculty of Pharmacy and look exactly like propolis tablets.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data is potentially shareable after unidentifiable individuals

When:
Starting 6 months after publication

To whom:
People working in academic institutions

Conditions:
Mention the source

Where to obtain:
Dr. Lili Hafizi Email: hafizil@mums.ac.ir Phone: 09153107633

How to obtain:
Reply to email within a maximum of one week

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Leili Hafizi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ebnesina Street, Imam Reza Hospital, Gynecology Department</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>٩١٣٧٩١٣٣١۶</zip>
        <telephone>+98 51 3802 2608</telephone>
        <email>hafizil@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr Leili Hafizi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Emam Reza Sq. Ebne-sina Ave, Emam Reza hosital</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9137913316</zip>
        <telephone>+98 51 3802 2608</telephone>
        <email>hafizil@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>All patients with a definite diagnosis of endometriosis by imaging and have pain due to endometriosis
Age between 20-45 years old
Use of standard progesterone hormone treatments
Not using NSAID medications
Not refer for infertility treatment
BMI between 18.5 to 27.5
Not taking food supplements
Obtaining the patient's informed consent</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>45 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Use of hormonal contraception and IUD during the last 3 months
Pregnancy or breastfeeding in the last 3 months
The presence of any physical and mental disease
Drug sensitivity to propolis</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N80.3</hc_code>
      <hc_code>N80.4</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Endometriosis of pelvic peritoneum</hc_keyword>
      <hc_keyword>Endometriosis of rectovaginal septum and vagina</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: standard treatment (progesterone drugs) along with propolis tablets 500 mg twice a day for 4 months. These tablets are made by the pharmaceutical laboratory of the Mashhad Faculty of Pharmacy and look exactly like placebo tablets.</i_keyword>
      <i_keyword>Control group: standard treatment (progesterone drugs) along with placebo tablets twice a day for 4 months. These tablets are made by the pharmaceutical laboratory of the Mashhad Faculty of Pharmacy and look exactly like propolis tablets.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Endometriosis pain. Timepoint: Before the intervention and 4months after the intervention. Method of measurement: Visual Analogue Scale (VAS).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mashhad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-05-22</approval_date>
        <contact_name>Ethics committee of Mashhad University of Medical Sciences</contact_name>
        <contact_address>Vice Chancellor for Research and Technology, Third floor of Ghoreshi building, Next to Hoveyzeh Cinema, Daneshgah Street, Mashhad Mashhad Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
